Nicholas Pulliam
Overview
Explore the profile of Nicholas Pulliam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
145
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhagwat S, Mur C, Vandekopple M, Zhao B, Shen W, Marugan C, et al.
Cancer Res
. 2024 Dec;
85(4):777-790.
PMID: 39652577
Targeting of the estrogen receptor (ER) by antiestrogens is the standard of care for patients with ER+ HER2- advanced/metastatic breast cancer. Although antiestrogens that degrade ERα (fulvestrant) or block estrogen...
2.
Gharbi S, Pelletier L, Espada A, Gutierrez J, Sanfeliciano S, Rauch C, et al.
NPJ Breast Cancer
. 2022 Dec;
8(1):133.
PMID: 36577758
No abstract available.
3.
Gharbi S, Pelletier L, Espada A, Gutierrez J, Sanfeliciano S, Rauch C, et al.
NPJ Breast Cancer
. 2022 Nov;
8(1):126.
PMID: 36446794
Despite the biological and therapeutic relevance of CDK4/6 for the treatment of HR+, HER2- advanced breast cancer, the detailed mode of action of CDK4/6 inhibitors is not completely understood. Of...
4.
Pulliam N, Tang J, Wang W, Fang F, Sood R, OHagan H, et al.
Cancers (Basel)
. 2019 Jan;
11(1).
PMID: 30621214
Therapeutic targeting of estrogen receptor-α (ERα) by the anti-estrogen tamoxifen is standard of care for premenopausal breast cancer patients and remains a key component of treatment strategies for postmenopausal patients....
5.
Tang J, Pulliam N, Ozes A, Buechlein A, Ding N, Keer H, et al.
Mol Cancer Res
. 2018 May;
16(8):1226-1240.
PMID: 29759990
Ovarian cancer (OC) cells frequently metastasize to the omentum, and adipocytes play a significant role in ovarian tumor progression. Therapeutic interventions targeting aberrant DNA methylation in ovarian tumors have shown...
6.
Pulliam N, Fang F, Ozes A, Tang J, Adewuyi A, Keer H, et al.
Clin Cancer Res
. 2018 Apr;
24(13):3163-3175.
PMID: 29615458
PARP inhibitors (PARPi) are primarily effective against BRCA1/2-mutated breast and ovarian cancers, but resistance due to reversion of mutated BRCA1/2 and other mechanisms is common. Based on previous reports demonstrating...
7.
Haley J, Tomar S, Pulliam N, Xiong S, Perkins S, Karpf A, et al.
Oncotarget
. 2016 May;
7(22):32810-20.
PMID: 27147568
Genomic analysis of ovarian cancer cell lines has revealed a panel that best represents the most common ovarian cancer subtype, high-grade serous ovarian cancer (HGSOC). However, these HGSOC-like cell lines...